Revolution Medicines
Develops RAS(ON) therapeutics for KRAS-driven and broad RAS-driven solid tumors.
$208.55
After-hours close+0.48 (+0.23%)
At close$208.07(−5.91%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 122.41%Insiders 1.82%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 212.60M · Float 190.10M · 89.4% free float
Institutions13F, as of Jun 30, 2026
732 holders · 260.24M shares · 246 new positions · 487 increased · 154 reduced · 67 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.70M | 6.44% | +2.48M | Aug 7, 2026 |
| Farallon Capital Management LLC | 13.55M | 6.37% | −54.0K | Aug 14, 2026 |
| FMR LLC | 12.20M | 5.74% | +3.74M | Aug 13, 2026 |
| Baker Bros. Advisors LP | 11.44M | 5.38% | +1.89M | Aug 14, 2026 |
| Jupiter Topco LLC | 10.74M | 5.05% | +10.74Mnew | Aug 14, 2026 |
| Darwin Global Management, Ltd. | 10.63M | 5.00% | +8.42M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 9.09M | 4.28% | +726.4K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 8.29M | 3.90% | +792.2K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.70% | 12.20M | 13G | Jul 29, 2026 ↗ |
| Baker Bros. Advisors LP | 5.30% | 11.44M | 13G | Aug 14, 2026 ↗ |
| JANUS HENDERSON GROUP Ltd. | 5.10% | 10.74M | 13G | Aug 13, 2026 ↗ |
| FMR LLC | 5.00% | 9.40M | 13G | Nov 5, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Alexis Borisy | director | 2.34M | 1.10% | Jun 23, 2026 |
| Mark A. Goldsmith | director, officer: See Remarks | 328.8K | 0.15% | Aug 25, 2026 |
| Stephen Michael Kelsey | officer: See Remarks | 291.9K | 0.14% | Jun 18, 2026 |
| Margaret A. Horn | officer: Chief Operating Officer | 154.6K | 0.07% | Jun 17, 2026 |
| Jack Anders | officer: Chief Financial Officer | 123.3K | 0.06% | Jun 26, 2026 |
| Xiaolin Wang | officer: See Remarks | 116.1K | 0.05% | Mar 19, 2026 |
| Lin Wei | officer: Chief Medical Officer | 101.4K | 0.05% | Mar 19, 2026 |
| Sandra Horning | director | 97.8K | 0.05% | Jun 23, 2026 |
| Lorence H. Kim | director | 74.3K | 0.03% | Jun 23, 2026 |
| Jeff Cislini | officer: General Counsel | 55.9K | 0.03% | Aug 25, 2026 |
4 ten-percent owners hold 9.59M shares by Form 4, outside the officers-and-directors figure above · 7 people have not refiled in the last 18 months (7.52M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 21, 2026 | Mark A. Goldsmithdirector, officer: See Remarks | Sale · 18 lots | 86,000 | $209.20 | 328,754 |
| Aug 21, 2026 | Jeff Cisliniofficer: General Counsel | Sale · 6 lots | 56,894 | $209.24 | 55,907 |
| Jun 29, 2026 | Sushil Pateldirector | Sale · 9 lots | 5,580 | $187.99 | 21,656 |
| Jun 24, 2026 | Jack Andersofficer: Chief Financial Officer | Sale · 4 lots | 20,000 | $168.33 | 123,269 |
| Jun 16, 2026 | Stephen Michael Kelseyofficer: See Remarks | Sale | 4,175 | $156.12 | 291,876 |
| Jun 16, 2026 | Jack Andersofficer: Chief Financial Officer | Sale | 2,722 | $156.12 | 123,269 |
| Jun 16, 2026 | Jeff Cisliniofficer: General Counsel | Sale | 2,157 | $156.12 | 56,521 |
| Jun 16, 2026 | Mark A. Goldsmithdirector, officer: See Remarks | Sale | 10,020 | $156.12 | 267,330 |
| Jun 16, 2026 | Anthony Manciniofficer: See Remarks | Sale | 4,615 | $156.12 | 49,975 |
| Jun 17, 2026 | Margaret A. Hornofficer: Chief Operating Officer | Sale | 29,600 | $160.12 | 154,647 |
CongressHouse and Senate disclosures
Not reported.